	Patient-reported outcomes of adjuvant therapy with CDK4/6 inhibitors for HR+/HER2- early breast cancer: a retrospective cohort study. BMC Cancer Cong B, Hou C, Shan C, Sun S, Sun S, Xia C, Wang Y. PMID: 41965632 [PubMed - as supplied by publisher]
	Serum 25-hydroxyvitamin D levels among women newly diagnosed with breast cancer at Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia. BMC Womens Health Meles M, Gutema G, Tsegaye M, Bashea C, Challa F, Bikila D, Gebremicael G, Getahun T, Habtu W, Alem M, Edao A, Carobene A, Tola HH. PMID: 41965576 [PubMed - as supplied by publisher]
	MRI-Based Habitat Analysis for Predicting Pathologic Complete Response to Neoadjuvant Chemotherapy in Breast Cancer: A Multicenter Study. J Magn Reson Imaging Zhu H, Zhang B, Peng D, Song S, Huang L, Zhang Y, Wu X. PMID: 41965129 [PubMed - as supplied by publisher]
	Editorial for "MRI-Based Habitat Analysis for Assessment of Pathologic Complete Response After Neoadjuvant Chemotherapy in Breast Cancer: A Multicenter Study". J Magn Reson Imaging Huang Y, Ren H. PMID: 41965128 [PubMed - as supplied by publisher]
	Selected Pathological Criteria That Predict Low Rates of Axillary Lymph Node Metastases Regardless of Patient Age: A Single Institution Study. Breast J Nathanson SD, Leonard-Murali S, Bui J, Chitale DA, Bensenhaver J, Schwartz T, Petersen L, Springer K, Baker P, Susick LL. PMID: 41964933 [PubMed - indexed for MEDLINE]
	The Predictive Value of the Tumor-Stroma Ratio for Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive Breast Cancer. Int J Cancer Andour L, Hagenaars SC, de Groot AF, Krol-Warmerdam EMM, Kroep JR, Hazelbag HM, Liefers GJ, Straver ME, Mesker WE. PMID: 41964157 [PubMed - as supplied by publisher]
	The role of small extracellular vesicles in ovarian cancer drug resistance: from bench clues to clinical implications. J Ovarian Res Chen J, Gu Z, Hua K, Zhang Y, Shen F, Zhang M, Zhou G, Ding J. PMID: 41964086 [PubMed - as supplied by publisher]
	Recent Advances in Surface-Engineered Polymeric Nanoparticles for Targeted Paclitaxel Delivery in Breast Cancer Therapy. AAPS PharmSciTech Fatima M, AlQahtani F, Kesharwani P. PMID: 41963751 [PubMed - indexed for MEDLINE]
	Neoadjuvant twelve weekly paclitaxel-carboplatin with trastuzumab and pertuzumab in HER2-positive breast cancer. Breast Cancer Res Treat Leshem Y, Golomb I, Zubkov A, Bar Y, Strulov Shachar S, Lerner S, Keren-Khadmy N, Sonnenblick A. PMID: 41963621 [PubMed - indexed for MEDLINE]
	PARP inhibitors and breast cancer: from therapeutic breakthrough to resistance challenge. Exp Mol Med Wang W, Cai C, Qin S, He L, Liang Q, Tang S, Xie J, Long T, Hou J, Kim W, Zhao F. PMID: 41963466 [PubMed - as supplied by publisher]
	Correspondence on "Comparison of survival outcomes and safety between early and late initiation of niraparib maintenance in newly diagnosed advanced epithelial ovarian cancer" by Kim et al. Int J Gynecol Cancer Song Y, Mao W, Chen Y, Wenren Y. PMID: 41963199 [PubMed - as supplied by publisher]
	Leydig cell ovarian tumour: a rare cause of hyperandrogenism. BMJ Case Rep Tseke D, Malkat S, Younes Y, Emmanuel J. PMID: 41962961 [PubMed - indexed for MEDLINE]
	3-POINT CORRECTION FACTOR IMPROVES ACCURACY OF FRAMINGHAM RISK SCORE IN BREAST CANCER SURVIVORS. Can J Cardiol Rickard JN, Christensen RAG, Williams JS, Abdel-Qadir H, Small SD, Santa Mina D, Kirkham AA. PMID: 41962842 [PubMed - as supplied by publisher]
	Association between inflammatory biomarkers and depressive symptoms in breast cancer: a systematic review. Brain Behav Immun Patel K, Karagiannis SN, Borsini A. PMID: 41962682 [PubMed - as supplied by publisher]
	Past, Present, and Future Perspectives in Estrogen-Receptor-Low Breast Cancer. Crit Rev Oncol Hematol Courtès DM, Florea DC, Anchisi S. PMID: 41962626 [PubMed - as supplied by publisher]
	Breast MRI features of idiopathic granulomatous mastitis and invasive breast carcinoma: A single-center comparative study. Clin Imaging Erkoc N, Karl, Tokoçin M, Gülkaç BÖ, Kalpako, Cimilli AT. PMID: 41962447 [PubMed - as supplied by publisher]
	Patient-reported outcomes and qualitative interviews in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: results from the phase III EMBER-3 trial. ESMO Open Curigliano G, O'Shaughnessy J, Bidard FC, Casalnuovo ML, Kim SB, Tokunaga E, Aftimos P, Saura C, Carey LA, Okera M, Melo E, Zagouri F, Magallanes-Maciel M, Karadurmus N, Bahadur S, Speck RM, Wang XA, Pradhan K, Macey J, Kitchen H, Fairhurst S, Miller J, Jhaveri KL, Harbeck N. PMID: 41962306 [PubMed - as supplied by publisher]
	Impact of hypofractionated radiotherapy schedules on local control in early breast cancer: A five-year study of boost vs. non-boost protocols. Appl Radiat Isot Najafizde N, Elhaie M, Mirlohi SH. PMID: 41962282 [PubMed - as supplied by publisher]
	Advanced Triple-Negative Breast Cancer: Emerging Therapies and a Changing Treatment Landscape. Am Soc Clin Oncol Educ Book Hennessy MA, Terman E, Idossa D, LeVee A, Leon-Ferre RA, McArthur H, Nanda R. PMID: 41962061 [PubMed - indexed for MEDLINE]
	Breast Cancer Risk Factors and Breast Complaints Among Kenyan Women. JCO Glob Oncol Odhiambo LA, Marion AJ, Mwaura WL, Mageto DK, Islam KM, Mwakisha J, Coughlin SS, Ojuka DK. PMID: 41962057 [PubMed - indexed for MEDLINE]

Articles 1 - 20 / 327199

Page 1 of 16360



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy